Kaleido Biosciences, a Phase 2 biotech developing microbiome therapies to treat rare genetic disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The Lexington, MA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol KLDO. Kaleido Biosciences filed confidentially on September 25, 2018. Goldman Sachs, J.P. Morgan and Morgan Stanley are the joint bookrunners on the deal. No pricing terms were disclosed.
